DENYES NANCY (General Counsel) sold 3.3% of their position (899.00 shares) of ATYR PHARMA INC on the open market
Open‑market sale worth $3.4K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/4/2025ACC: 0000950170-25-013878
Officer· General Counsel
Since Feb 2019
-899.00
Net shares
Net seller
$3.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
2.69K acquired · 3.59K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+2.69K
Price / share
—
Trade value
—
% of position
10.8%
2/3/2025
24.77K→27.45K
Common Stock
Direct
Shares
−899.00
Price / share
$3.78
Trade value
$3.40K
% of position
3.3%
2/4/2025
27.45K→26.55K
Total
Net shares
+1.79K
Net value
-$3.40K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/3/2025 | M · Option Exercise | +2.69K | — | — | 10.8% | 24.77K | 27.45K |
| Common Stock Direct | 2/4/2025 | S · Sale | −899.00 | $3.78 | $3.40K | 3.3% | 27.45K | 26.55K |
| Total | +1.79K | -$3.40K | ||||||
Derivative Transactions1
Restricted Stock Unit
Direct
Converts to
Common Stock
2.69K shares
Shares
−2.69K
Strike price
Held after
2.69K
Exercisable
—
2/3/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Unit Direct | Common Stock2.69K shares | 2/3/2025 | M · Option Exercise | −2.69K | — | 2.69K |